Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
coronavirus
MedTech
Testmaker Cue Health under investor pressure to change course
Cue’s stock value has since slid into sub-dollar territory, dropping nearly 98% from the high of $20 when it went public down to about 50 cents today.
Conor Hale
Aug 31, 2023 12:01pm
CDC works to overhaul lab operations after COVID test flop
Aug 21, 2023 10:45am
Cue wins FDA's first de novo nod for an at-home COVID test
Jun 7, 2023 10:13am
Pardes plans descent from COVID-19 antiviral flight path
Apr 3, 2023 10:25am
FDA finalizes plans for the future of COVID tests, devices
Mar 27, 2023 10:25am
Immunome decides not to top up its COVID antibody cocktail
Mar 16, 2023 10:05am